Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413766 | 0.98 | LTB4R (0.60) | FFAR1LTB4RLTB4R2DHFRPPARD | |
| SCHEMBL8081157 | 0.86 | LTB4R (0.67) | LTB4RLTB4R2DHFRPPARDPPARG | |
| SCHEMBL3550795 | 0.85 | FFAR1 (0.51) | FFAR1LTB4RLTB4R2DHFRALDH1A1 | |
| SCHEMBL11668948 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2DHFRPPARDPPARG | |
| SCHEMBL19160930 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2DHFRPPARDPPARG | |
| SCHEMBL10697320 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2DHFRPPARDPPARG | |
| SCHEMBL8084778 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2DHFRPPARDPPARG | |
| SCHEMBL8081137 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2DHFRPPARDPPARG | |
| SCHEMBL8072582 | 0.84 | LTB4R (0.64) | LTB4RLTB4R2DHFRALDH1A1PPARD | |
| SCHEMBL8285810 | 0.84 | LTB4R (0.57) | FFAR1LTB4RLTB4R2DHFRPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| WO-2016002948-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | 国立大学法人東京大学 | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | LPAR3, LPAR1, LPAR4 | FFAR1 84/4885LTB4R 92/4885LTB4R2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.